GSK Pivotal Phase III Study of Darapladib in Chronic Coronary Heart Disease Gid Not Meet Primary Endpoint

GlaxoSmithKline (NYSE: GSK ) today announced top-line results from the Phase III STABILITY trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY), evaluating the efficacy of its investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary heart disease (CHD). Darapladib is not approved for use anywhere in